Vertex, Inc. (VERX) is scheduled to report fourth-quarter 2024 results before market open on Feb. 27.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The Zacks Consensus Estimate for Vertex’s fourth-quarter 2024 earnings is pegged at 14 cents per share, implying a year-over-year increase of 7.7%.Vertex’s earnings surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 15.8%.Vertex expects its fourth-quarter 2024 revenues to be in the ran ...

The upcoming report from Vertex (VERX) is expected to reveal quarterly earnings of $0.14 per share, indicating an increase of 7.7% compared to the year-ago period. Analysts forecast revenues of $176.63 million, representing an increase of 14% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it is of utm ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And investors become more bullish about its long-term prospects, and the potential the stock has to rise higher in value.Vertex Pharmaceuticals (VRTX 2.07%) has many promising treatments in its pipeline, as it looks to build out its business beyond just the cystic fibrosis (CF) drugs that have enabled it to post strong ...

Here's our initial take on Vertex Pharmaceuticals' (VRTX 0.14%) fourth-quarter financial report.Key MetricsMetricQ4 2023Q4 2024Changevs. ExpectationsRevenue$2.52 billion$2.91 billion16%BeatEarnings per share$3.71$3.50-6%MissedTrikafta/Kaftrio revenue$2.33 billion$2.72 billion17%n/aOther product revenue$184.4 million$191.2 million4%n/aVertex reported solid fourth-quarter numbers throughout its business. While the company's earnings per share came in slightly shy of expectations, top-line revenue growth was a ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.Vertex Pharmaceuticals(VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion. This top-line improvement was largely due to the continued success of its cystic fibrosis lineup, particularly Trikafta/Kaftrio. However, non-GAAP earnings per ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations.  The company said it anticipates 2025 revenue of $11.75 billion to $12 billion, representing nearly 20% growth from 2024 at the midpoint and well above analysts’ projections compiled by Visible Alpha.  Vertex's fourth-quarter revenue of $2.91 billion was up 16% year-over-year and also exceeded the analyst consensus. Adjusted earnings of $1.04 billion, or $3.98 per share, fell fr ...

Vertex Pharmaceuticals (VRTX 1.88%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.The biotech just won regulatory approval for Journavx (formerly known as suzetrigine) for the treatment of acute pain -- the sort of pain you may have after an accident or sur ...

Vertex Pharmaceuticals (VRTX 5.31%) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF). Last Thursday, the agency approved Vertex's Journavx in treating adults with moderate-to-severe acute pain. Unsurprisingly, investors reacted positively to the latest regulatory victory, with Vertex's shares jumping on Friday. Is this biotech stock a no-brainer buy now after its huge FDA approval ...

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (VRTX 5.31%) are down about 9% from a peak the stock set in November, despite some highly positive news.The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the peripheral nervous system.Each year, around 80 million Americans are prescribed ...

I’m a stock analyst with an MBA and a background in healthcare, bringing years of experience as a Registered Nurse dedicated to patient care. I've had the privilege of sharing my insights on Seeking Alpha since 2017. I am most interested in identifying underlying assumptions in stock valuations by emphasizing financial modeling techniques like DCF analysis. I then provide scenario-based forecasts to help readers gauge reasonable outcomes. I am influenced by books like Superforecasting and Antifragile. As su ...